Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Diabetologia ; 55(10): 2741-2746, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22854889

RESUMO

AIMS/HYPOTHESIS: Plasma ceramide concentrations correlate with insulin sensitivity, inflammation and atherosclerotic risk. We hypothesised that plasma ceramide concentrations are increased in the presence of elevated fatty acid levels and are regulated by increased liver serine C-palmitoyltransferase (SPT) activity. METHODS: Lean humans and rats underwent an acute lipid infusion and plasma ceramide levels were determined. One group of lipid-infused rats was administered myriocin to inhibit SPT activity. Liver SPT activity was determined in lipid-infused rats, and obese, insulin resistant mice. The time and palmitate dose-dependent synthesis of intracellular and secreted ceramide was determined in HepG2 liver cells. RESULTS: Plasma ceramide levels were increased during lipid infusion in humans and rats, and in obese, insulin-resistant mice. The increase in plasma ceramide was not associated with changes in liver SPT activity, and inhibiting SPT activity by ~50% did not alter plasma ceramide levels in lipid-infused rats. In HepG2 liver cells, palmitate incorporation into extracellular ceramide was both dose- and time-dependent, suggesting the liver cells rapidly secreted the newly synthesised ceramide. CONCLUSIONS/INTERPRETATION: Elevated systemic fatty acid availability increased plasma ceramide but this was not associated with changes in hepatic SPT activity, suggesting that liver ceramide synthesis is driven by substrate availability rather than increased SPT activity. This report also provides evidence that the liver is sensitive to the intracellular ceramide concentration, and an increase in liver ceramide secretion may help protect the liver from the deleterious effects of intracellular ceramide accumulation.


Assuntos
Ceramidas/sangue , Ácidos Graxos/farmacologia , Fígado/metabolismo , Serina C-Palmitoiltransferase/metabolismo , Adulto , Animais , Ceramidas/metabolismo , Modelos Animais de Doenças , Feminino , Células Hep G2/metabolismo , Humanos , Resistência à Insulina/fisiologia , Masculino , Camundongos , Camundongos Obesos , Modelos Animais , Obesidade/metabolismo , Ratos , Ratos Wistar
2.
Diabetologia ; 54(1): 146-56, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20842343

RESUMO

AIMS/HYPOTHESIS: Hepatic steatosis is characterised by excessive triacylglycerol accumulation and is strongly associated with insulin resistance. An inability to efficiently mobilise liver triacylglycerol may be a key event mediating hepatic steatosis. Adipose triacylglycerol lipase (ATGL) is a key triacylglycerol lipase in the liver and we hypothesised that liver-specific overproduction of ATGL would reduce steatosis and enhance insulin action in obese rodents. METHODS: Studies of fatty acid metabolism were conducted in primary hepatocytes isolated from wild-type and Atgl (also known as Pnpla2)⁻(/)⁻ mice. An ATGL adenovirus was utilised to overproduce ATGL in the livers of obese insulin-resistant C57Bl/6 mice (Ad-ATGL). Blood chemistry, hepatic lipid content and insulin sensitivity were assessed in mice. RESULTS: Triacylglycerol content was increased in Atgl⁻(/)⁻ hepatocytes and was associated with increased fatty acid uptake and impaired fatty acid oxidation. ATGL adenovirus administration in obese mice increased the production of hepatic ATGL protein and reduced triacylglycerol, diacylglycerol and ceramide content in the liver. Overproduction of ATGL improved insulin signal transduction in the liver but did not affect fasting glycaemia or insulinaemia. Inflammatory signalling was not suppressed by ATGL overproduction. While ATGL overproduction increased plasma non-esterified fatty acids, neither lipid deposition nor insulin-stimulated glucose uptake were affected in skeletal muscle. CONCLUSIONS/INTERPRETATION: Liver ATGL overproduction decreases hepatic steatosis and mildly enhances liver insulin sensitivity. These effects are not sufficient to improve fasting glycaemia or insulinaemia in rodent obesity.


Assuntos
Resistência à Insulina/fisiologia , Lipase/metabolismo , Metabolismo dos Lipídeos/fisiologia , Fígado/efeitos dos fármacos , Fígado/metabolismo , Animais , Western Blotting , Resistência à Insulina/genética , Lipase/genética , Metabolismo dos Lipídeos/genética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Mutantes , Camundongos Obesos , Reação em Cadeia da Polimerase
3.
Diabetologia ; 54(6): 1417-26, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21331471

RESUMO

AIMS/HYPOTHESIS: To determine if acute overexpression of peroxisome proliferator-activated receptor, gamma, coactivator 1 beta (Pgc-1ß [also known as Ppargc1b]) in skeletal muscle improves insulin action in a rodent model of diet-induced insulin resistance. METHODS: Rats were fed either a low-fat or high-fat diet (HFD) for 4 weeks. In vivo electroporation was used to overexpress Pgc-1ß in the tibialis cranialis (TC) and extensor digitorum longus (EDL) muscles. Downstream effects of Pgc-1ß on markers of mitochondrial oxidative capacity, oxidative stress and muscle lipid levels were characterised. Insulin action was examined ex vivo using intact muscle strips and in vivo via a hyperinsulinaemic-euglycaemic clamp. RESULTS: Pgc-1ß gene expression was increased >100% over basal levels. The levels of proteins involved in mitochondrial function, lipid metabolism and antioxidant defences, the activity of oxidative enzymes, and substrate oxidative capacity were all increased in muscles overexpressing Pgc-1ß. In rats fed a HFD, increasing the levels of Pgc-1ß partially ameliorated muscle insulin resistance, in association with decreased levels of long-chain acyl-CoAs (LCACoAs) and increased antioxidant defences. CONCLUSIONS: Our data show that an increase in Pgc-1ß expression in vivo activates a coordinated subset of genes that increase mitochondrial substrate oxidation, defend against oxidative stress and improve lipid-induced insulin resistance in skeletal muscle.


Assuntos
Acil Coenzima A/metabolismo , Resistência à Insulina/fisiologia , Metabolismo dos Lipídeos/fisiologia , Músculo Esquelético/metabolismo , Estresse Oxidativo/fisiologia , Proteínas de Ligação a RNA/metabolismo , Fatores de Transcrição/metabolismo , Animais , Gorduras na Dieta/efeitos adversos , Masculino , Mitocôndrias Musculares/fisiologia , Modelos Animais , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio/metabolismo , Fatores de Tempo
4.
J Physiol Pharmacol ; 60(3): 155-60, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19826194

RESUMO

This study used a novel in vivo model to test the hypothesis that nutritive and non-nutritive blood flow distribution can still be observed under conditions of high vascular tone and oxygen delivery at rest and in metabolically active (twitch contracting) skeletal muscle. Experiments were performed in a constant flow autologous pump-perfused hindlimb in anaesthetised male Wistar rats. Agonists were tested at rest with a flow rate of 1ml x min(-1), and during hindlimb muscle twitch contractions (sciatic nerve stimulation: 6V, 1Hz, 0.05ms, 3min) at a flow rate of 2ml x min(-1). Oxygen consumption was determined from hindlimb venous and arterial blood samples. Resting perfusion pressure at 1ml x min(-1) was 92 + or - 3 mmHg (N=15) and oxygen consumption was 0.41 + or - 0.05 micromol x min(-1) x g(-1). Serotonin increased perfusion pressure and significantly decreased basal hindlimb oxygen consumption at rest. During acute muscle contraction this effect on oxygen consumption was diminished. Noradrenaline significantly increased perfusion pressure but had no significant effect on basal hindlimb oxygen consumption. Vasoconstriction that impacts upon muscle metabolism occurs in vivo, which potentially could be due to selective redistribution of blood flow. However, during muscle contraction local release of vasodilatory regulation can overcome exogenously-induced vasoconstriction. These results support the hypothesis that dual vascular pathways may explain differential vasoconstriction and how it impacts upon muscle metabolism.


Assuntos
Contração Muscular/efeitos dos fármacos , Relaxamento Muscular/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Consumo de Oxigênio/efeitos dos fármacos , Vasoconstrição/efeitos dos fármacos , Vasoconstritores/farmacologia , Animais , Relação Dose-Resposta a Droga , Membro Posterior/irrigação sanguínea , Membro Posterior/efeitos dos fármacos , Membro Posterior/metabolismo , Masculino , Músculo Esquelético/irrigação sanguínea , Músculo Esquelético/metabolismo , Perfusão , Pressão , Ratos , Ratos Wistar , Fluxo Sanguíneo Regional/efeitos dos fármacos , Vasoconstritores/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA